Atlantic Health Treats First Patient in Northeast for Glioblastoma with New Cellular Immunotherapy in Phase 2 Clinical Trial
The experimental combination of nivolumab and relatlimab may provide benefit for people newly diagnosed with IDH wildtype glioblastoma.
This Phase 2 trial evaluates the safety and potential efficacy of combining nivolumab and relatlimab in adults with newly diagnosed IDH wildtype glioblastoma (ndGBM) before and after surgery, with subsequent radiation and optional temozolomide.
Determining whether immunotherapy with nivolumab and relatlimab can improve outcomes for patients with IDH wildtype glioblastoma, a disease with limited treatment options.
Bizonyítékszint: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.
Kapcsolódó jelek
- Glioma
- Glioblastoma Clinical Trials for New Treatments
- Clinical trial links oncolytic immunoactivation to survival in glioblastoma
- Treating the invisible target: treatment planning targeting the microscopic tumor spread in gliomas
- EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma